Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin
Tóm tắt
Từ khóa
Tài liệu tham khảo
Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418:650–654
Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S (2003) Acute effects of PYY3–36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311:915–919
Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 349:941–948
Tschop M, Castaneda TR, Joost HG et al (2004) Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430:1
Korner J, Bessler M, Cirilo LJ et al (2005) Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359–365
Mantzoros CS (1999) The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 130:671–680
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077
Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS (2003) The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 111:1409–1421
Chan JL, Moschos SJ, Bullen J et al (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-α receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90: 1625–1631
Wong SL, DePaoli AM, Lee JH, Mantzoros CS (2004) Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metab 89:2672–2677
Alvarez BM, Borque M, Martinez-Sarmiento J et al (2002) Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 12:324–327
Considine RV, Sinha MK, Heiman ML et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295
Heymsfield SB, Greenberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575
Chan JL, Bullen J, Lee JH, Yiannakouris N, Mantzoros CS (2004) Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects. J Clin Endocrinol Metab 89:335–343
Kiely JM, Graewin SJ, Pitt HA, Swartz-Basile DA (2005) Leptin increases small intestinal response to cholecystokinin in leptin-deficient obese mice. J Surg Res 124:146–150
Troupin B, Lush C, Chen K et al (2005) A phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of rising doses of AC162352 (synthetic human PYY3–36) in lean and obese subjects. Endocrine Society Meeting, 4–7 June, 2005, San Diego: oral presentation (Abstract)